How Silexion’s Preclinical Breakthrough for SIL204 Drives a 61% After-Hours Stock Surge
Explore Silexion Therapeutics’ 61% after‑hours surge as preclinical data for KRAS‑targeting SIL204 shows efficient systemic delivery, boosting investor confidence.
2 minutes to read